ADMA Biologics, Inc. (ADMA)

ADMA's stock price has experienced a significant decline over the past six months. A major event impacting the stock was a short seller report published by Culper Research on March 24, 2026, which led to a 16% stock slide. ADMA Biologics denied these allegations, stating the report contained "misleading, false and inaccurate statements." Prior to this, in February 2026, ADMA reported strong fourth quarter and full-year 2025 financial results, including record ASCENIV demand and significant revenue growth. In August 2025, ADMA completed a syndicated debt refinancing to lower borrowing costs and enhance financial flexibility, and announced a $14.5 million expansion of its Florida biologics campus.

While there is record ASCENIV demand, strong prescriber adoption and broad payer access, specific details regarding the seasonality of demand for ADMA Biologics' products are not explicitly provided. The company's focus on immune globulin therapies for immune-compromised patients suggests a consistent medical need rather than strong seasonal fluctuations, but no direct information confirms or denies this.

ADMA Biologics, Inc. is a U.S.-based specialty biopharmaceutical company focused on the development, manufacturing, and commercialization of plasma-derived biologics. The company operates within the Healthcare sector, specifically in the Biopharmaceuticals, plasma-derived therapeutics, Drugs, and Pharmaceuticals industries. ADMA's major products, all FDA-approved and derived from human plasma, include ASCENIV™, BIVIGAM®, and NABI-HB®. These immune globulin therapies are primarily used for the treatment of primary humoral immunodeficiency (PI) and for the prevention of hepatitis B recurrence following liver transplantation, targeting immune-compromised patient populations at risk of infection. The company also operates source plasma collection facilities through its ADMA BioCenters subsidiary.

ADMA Biologics' operations are primarily concentrated in the United States. Its corporate headquarters are located in Ramsey, New Jersey. The company maintains plasma collection centers across multiple U.S. states, including Georgia and Texas, and its manufacturing operations are centralized in Boca Raton, Florida. ADMA's commercial activities are focused on U.S. healthcare providers and institutions, and it does not currently maintain significant direct international operations. The company emphasizes its fully U.S.-based, vertically integrated supply chain, which is designed to enhance supply reliability, cost control, and insulate it from global trade disruptions.

ADMA Biologics' brand reputation in the past year has been significantly impacted by a short seller report from Culper Research in March 2026. The report made allegations of "channel stuffing" and questioned the company's financial reporting practices, leading to a notable drop in stock price and an investigation by a shareholders rights firm. ADMA publicly refuted these claims, characterizing them as "misleading, false and inaccurate statements." Despite these allegations, ADMA reported strong financial results for the fourth quarter and full year 2025, with record demand for its product ASCENIV, and maintains a "GREAT" financial health score according to InvestingPro analysis.

ADMA Biologics' ownership structure is a mix of institutional, retail, and individual investors. Institutional investors hold a substantial portion of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, State Street Corp, Invesco Ltd., Sachem Head Capital Management LP, Westfield Capital Management Co Lp, Capital Research Global Investors, Nuveen, LLC, Geode Capital Management, Llc, and American Century Companies Inc. Insiders own approximately 3.26% of the stock, while public companies and individual investors hold a significant portion.